MBX Biosciences
63 hedge funds and large institutions have $606M invested in MBX Biosciences in 2024 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 11 increasing their positions, 8 reducing their positions, and 15 closing their positions.
120% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 15
40% more funds holding
Funds holding: 45 → 63 (+18)
38% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 8
3.33% more ownership
Funds ownership: 95.24% → 98.57% (+3.3%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
23% less capital invested
Capital invested by funds: $784M → $606M (-$178M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$15.5M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$13.2M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$12.8M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$5.19M |
| 5 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$3.62M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$2.28M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$1.72M |
| 3 |
MS
Maven Securities
St Helier,
Jersey
|
-$1.3M |
| 4 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$1.3M |
| 5 |
SC
Stempoint Capital
New York
|
-$1.3M |
MBX Hedge Fund Activity: Q4 2024 in Review
63 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in MBX Biosciences (MBX) for Q4 2024, worth a combined $606M — down 23% from $784M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new MBX positions and 15 closed out — a net gain of 18 holders — while 11 added to existing stakes and 8 trimmed.
The largest buyer was BlackRock, opening a new position worth an estimated $15.5M. The largest seller was Millennium Management, cutting an estimated $2.28M.
- 63 institutional investors held MBX Biosciences (MBX) as of Q4 2024, up from 45 in Q3 2024.
- Funds reported $606M of MBX Biosciences stock for Q4 2024, down 23% quarter-over-quarter.
- 33 funds opened new MBX Biosciences positions in Q4 2024 and 15 closed out, a net change of +18 holders.
- The largest MBX Biosciences buyer in Q4 2024 was BlackRock, an estimated $15.5M added.
- The largest MBX Biosciences seller in Q4 2024 was Millennium Management, an estimated $2.28M sold.
Based on aggregated 13F filings for Q4 2024.